SCHEMBL4117351

SCHEMBL4117351

Oc1cccc(-c2nc(N3CCOCC3)c3[nH]cc(C4CCN(Cc5ccc[nH]5)CC4)c3n2)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 20/20 0.79
MTOR P42345 16/20 0.79
PIK3CG P48736 9/20 0.51
PIK3CD O00329 3/20 0.48
PIK3CB P42338 2/20 0.48
PIK3C2A O00443 1/20 0.46
PIK3C2B O00750 1/20 0.46
CHUK O15111 1/20 0.46
DAPK3 O43293 1/20 0.46
PIK3C2G O75747 1/20 0.46
RAF1 P04049 1/20 0.46
BRAF P15056 1/20 0.46
CSNK2A2 P19784 1/20 0.46
JAK1 P23458 1/20 0.46
PIK3R1 P27986 1/20 0.46
TYK2 P29597 1/20 0.46
FLT3 P36888 1/20 0.46
CLK1 P49759 1/20 0.46
CLK2 P49760 1/20 0.46
CLK3 P49761 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3995463 0.89 PIK3CA (1.00) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL4119533 0.87 PIK3CA (0.77) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL4245690 0.86 PIK3CA (0.78) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL3989751 0.86 PIK3CA (1.00) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL3989557 0.86 PIK3CA (0.80) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL3992680 0.86 PIK3CA (0.80) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL3998727 0.85 PIK3CA (0.77) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL3995251 0.85 PIK3CA (0.81) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL3996938 0.84 PIK3CA (0.74) PIK3CAMTORPIK3CGPIK3CDPIK3CB
SCHEMBL3991337 0.84 PIK3CA (0.81) PIK3CAMTORPIK3CGPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149458-A1 PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS WYETH (US) 2009-06-11 US claimed
WO-2009070524-A1 PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND MTOR KINASE INHIBITORS WYETH (US) 2009-06-04 WO claimed
US-20090149458-A1 PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS WYETH (US) 2009-06-11 US disclosed
WO-2009070524-A1 PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND MTOR KINASE INHIBITORS WYETH (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149458-A1 PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS MTOR, PIK3CA, PIK3CD PIK3CA 2/4885MTOR 1/4885PIK3CG 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.